Evidence map›Paper›PMID 28915667›Full record

ArticleOncotarget2017

Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography.

Parul Gupta, Jo-Ann Wentland, Mauricio Leal, Dangshe Ma, Rachel Roach, Antonio Esparza, Lindsay King, Mary E Spilker, Cedo Bagi, Christopher T Winkelmann and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Parul GuptaGlobal Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA.
Jo-Ann WentlandPharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA.
Mauricio LealPharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA.
Dangshe MaOncology Research Unit, Pfizer, Inc., Pearl River, NY, USA.
Rachel RoachCenter for Therapeutic Innovation, Pfizer, Inc., La Jolla, CA, USA.
Antonio EsparzaComparative Medicine, Pfizer, Inc., La Jolla, CA, USA.
Lindsay KingPharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA.
Mary E SpilkerPharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA.
Cedo BagiGlobal Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA.
Christopher T WinkelmannGlobal Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA.
Anand GiddabasappaGlobal Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA.
Pfizer (United States) · USGlobal Science & Technology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-invasive imaging using radiolabels is a common technique used to study the biodistribution of biologics. Due to the limited shelf-life of radiolabels and the requirements of specialized labs, non-invasive optical imaging is an attractive alternative for preclinical studies. Previously, we demonstrated the utility of fluorescence molecular tomography (FMT) an optical imaging modality in evaluating the biodistribution of antibody-drug conjugates. As FMT is a relatively new technology, few fluorophores have been validated for

Indexed as

biodistributionbiotherapeuticsfluorescence molecular tomography (FMT)molecular imagingtumor targeting

Identifiers

PMID28915667
PMCPMC5593638
OpenAlexW2738650803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.